Eutilex.Co.,Ltd (KOSDAQ: 263050)

Market Cap	72.27B
Revenue (ttm)	6.89B
Net Income (ttm)	-25.34B
Shares Out	36.79M
EPS (ttm)	-689.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81,972
Open	2,045.00
Previous Close	1,998.00
Day's Range	1,955.00 - 2,045.00
52-Week Range	1,765.00 - 3,700.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 21, 2025

About Eutilex.Co.,Ltd

Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headquartered in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 263050

Financial Performance

In 2023, Eutilex.Co.,Ltd's revenue was 131.65 million, a decrease of -38.95% compared to the previous year's 215.66 million. Losses were -27.72 billion, -17.08% less than in 2022.